Cancer diagnostics company recognized by Los Angeles Business Journal for success in healthcare innovation
LOS ANGELES, November 05, 2014 – Cynvenio Biosystems, Inc. announced today that it has been named a finalist for the Los Angeles Business Journal's 2014 Patrick Soon-Shiong Innovation Awards. The awards program, now in its fifth year, was created to celebrate the region’s most impactful innovators who, alongside Dr. Soon-Shiong, CEO at NantWorks, LLC, play an important role in enhancing the economic competitiveness of the region.
“It’s an honor to have our LiquidBiopsy® and ClearID™ technology recognized by someone with Dr. Soon-Shiong’s expertise in gene sequencing, as well as the distinguished advisory committee for the Innovation Awards,” said André de Fusco, CEO of Cynvenio. “We are entering a radically new and promising age in oncology, and this type of recognition inspires our team to push ahead in the development of personalized cancer solutions for targeted therapy.”
Fifteen finalists were selected this year to compete for five awards. An independent judging panel will name the 2014 recipients at an awards dinner on November 18 at the Beverly Wilshire Hotel in Beverly Hills. The November 24th edition of the business journal will include a special feature on the program.
The advisory committee for this year’s awards includes: Matt Toledo, CEO and Publisher, Los Angeles Business Journal; Patrick Soon-Shiong, Chairman & CEO, NantWorks; Bill Allen, CEO, Los Angeles County Economic Development Corporation; Jim Ellis, Dean, Marshall School of Business, USC; Frederic Farina, Director of Tech Transfer, Caltech; Eric Grey, Managing Director, Merrill Lynch; Judy Olian, Dean, Anderson School of Management, UCLA; Josh Schimmels, Associate Publisher, Los Angeles Business Journal and Gary Toebben, CEO, Los Angeles Area Chamber of Commerce.
About Cynvenio Biosystems, Inc.
Cynvenio is a molecular information technology company focused on individualizing cancer treatment by providing longitudinal insights into each patient via the genomic analysis of their cancer from a standard blood draw.Cynvenio’s LiquidBiopsy® and ClearID™ clinical assays for solid tumors are used as therapy finders to periodically assess patients’ individual mutations and match them with targeted cancer therapies and clinical trials. Both blood tests can be used to complement traditional tissue biopsy analysis, or as standalone tests to find therapies for patients in which tissue biopsy is deemed difficult or too risky to harvest.Cynvenio is headquartered in Westlake Village, California (Los Angeles). For more information, visit http://www.cynvenio.com.
LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.
About the Patrick Soon-Shiong Innovation Awards
For the fifth year, the Los Angeles Business Journal and NantWorks are proud to co-host the Patrick Soon-Shiong Innovation Awards. California is home to some of the most cutting-edge and innovative companies in the country. Innovation comes in many forms from finished products and processes to implementation and idea generation. As a true and accomplished innovator himself, Dr. Soon-Shiong recognizes the important role that innovation plays in enhancing the economic competitiveness of the region. This special award program was created to honor and acknowledge the people and organizations that continue to stretch the boundaries and have proven to be leaders in innovation. For more information, visithttp://www.labusinessjournal.com.